Engineered Probiotic Yeast Produces Gut-Opening Peptides to Help Drugs Get Absorbed Orally
Probiotic yeast engineered to produce cell-penetrating peptides in the gut successfully enhanced intestinal absorption of a large molecule in mice — a first-of-its-kind approach to oral drug delivery.
Quick Facts
What This Study Found
Researchers engineered the probiotic yeast Saccharomyces boulardii to produce cell-penetrating peptides (CPPs) directly inside the gut, enhancing intestinal absorption of large molecules. Four different CPPs were integrated into the yeast's chromosome: RRL helix, Shuffle, Penetramax, and PN159. In cell culture (Caco-2 model), three of the four CPP-producing strains increased intestinal permeability without causing permanent damage to the gut lining.
In live mice, the PN159-producing yeast strain significantly increased FITC-dextran (a model macromolecule) absorption into the bloodstream over 10 days — without causing gut inflammation. This is the first demonstration that an engineered microorganism can modulate host intestinal permeability to improve macromolecule absorption.
Key Numbers
4 CPPs tested · 3/4 effective in vitro · Sb PN159 effective in vivo · 10-day mouse study · No inflammation · First-in-class demonstration
How They Did This
Cell-penetrating peptide genes were chromosomally integrated into S. boulardii probiotic yeast. In vitro testing used Caco-2 intestinal cell monolayers to assess permeability changes and cell damage. In vivo experiments administered the engineered yeast to mice for 10 days, then measured FITC-dextran translocation from gut to bloodstream as a proxy for macromolecule absorption. Inflammation markers were assessed to confirm safety.
Why This Research Matters
The biggest barrier to oral peptide drugs is that they get destroyed in the stomach or can't cross the intestinal wall. This study proposes an elegant solution: a living probiotic yeast that colonizes your gut and continuously produces peptides that temporarily open the intestinal barrier, allowing therapeutic molecules to pass through. If this approach works for actual peptide drugs (not just model molecules), it could eliminate the need for injections for many peptide therapies.
The Bigger Picture
Oral peptide delivery is the holy grail of peptide therapeutics. Current solutions like SNAC (used for oral semaglutide) work but have limitations. Using a living probiotic as a drug delivery vehicle represents a completely new paradigm — the yeast continuously produces absorption-enhancing peptides exactly where they're needed. If this technology matures, it could transform peptide therapeutics by making oral versions of currently injectable drugs like insulin, GLP-1 agonists, and growth hormone peptides feasible.
What This Study Doesn't Tell Us
The study used FITC-dextran as a model macromolecule — not an actual peptide drug — so therapeutic absorption remains unproven. Mouse gut physiology differs from human gut. Increased intestinal permeability could theoretically allow unwanted molecules (bacteria, toxins) to enter the bloodstream too, raising long-term safety questions. The 10-day study duration doesn't address chronic use effects. Regulatory pathway for a genetically engineered probiotic would be complex.
Questions This Raises
- ?Will this approach work with actual peptide drugs and not just model molecules like FITC-dextran?
- ?Could chronically increasing intestinal permeability pose long-term safety risks, such as allowing harmful molecules or bacteria to enter the bloodstream?
- ?How would regulators evaluate a genetically engineered probiotic designed to alter gut permeability?
Trust & Context
- Key Stat:
- First-ever living delivery vehicle This is the first demonstration that an engineered microorganism can modulate intestinal permeability to improve macromolecule absorption — using cell-penetrating peptides produced by probiotic yeast in the gut
- Evidence Grade:
- This is a novel proof-of-concept study with both in vitro (cell culture) and in vivo (mouse) validation, published in the high-impact journal Trends in Biotechnology. While the first-in-class nature is exciting, the use of a model molecule rather than actual drugs, the mouse model, and short study duration limit the translational confidence.
- Study Age:
- Published in 2025, this is cutting-edge research at the forefront of synthetic biology and peptide drug delivery. The approach is early-stage but represents a potentially transformative technology direction.
- Original Title:
- Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract.
- Published In:
- Trends in biotechnology, 43(3), 715-731 (2025)
- Authors:
- Gelli, Hitesh P(2), Hedin, Karl Alex, Laursen, Martin F, Uribe, Ruben-Vazquez, Sommer, Morten Otto Alexander
- Database ID:
- RPEP-11079
Evidence Hierarchy
Frequently Asked Questions
How does an engineered yeast help with drug absorption?
The probiotic yeast Saccharomyces boulardii was genetically modified to produce cell-penetrating peptides (CPPs) inside the gut. These peptides temporarily open tight junctions between intestinal cells, creating passages that allow large drug molecules to cross from the gut into the bloodstream. Because the yeast is alive and producing CPPs continuously in the right location, it provides sustained absorption enhancement exactly where oral drugs need to cross.
Is it safe to increase intestinal permeability?
That's the key question. In this 10-day mouse study, the engineered yeast increased permeability enough to boost macromolecule absorption but did not cause gut inflammation — which is encouraging. However, the intestinal barrier exists to keep harmful substances out, so long-term safety studies are essential. The researchers need to confirm that the permeability increase is selective enough to let drugs through without opening the door to bacteria or toxins.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11079APA
Gelli, Hitesh P; Hedin, Karl Alex; Laursen, Martin F; Uribe, Ruben-Vazquez; Sommer, Morten Otto Alexander. (2025). Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract.. Trends in biotechnology, 43(3), 715-731. https://doi.org/10.1016/j.tibtech.2024.10.019
MLA
Gelli, Hitesh P, et al. "Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract.." Trends in biotechnology, 2025. https://doi.org/10.1016/j.tibtech.2024.10.019
RethinkPeptides
RethinkPeptides Research Database. "Enhancing intestinal absorption of a macromolecule through e..." RPEP-11079. Retrieved from https://rethinkpeptides.com/research/gelli-2025-enhancing-intestinal-absorption-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.